Brain mapping and neurofeedback: what the evidence says

Brain mapping and neurofeedback are tools used alongside therapy, not replacements for it. Research on neurofeedback for substance use is growing and looks promising, but the studies are small and use many different methods.

For PTSD, a major federal guideline found there is not enough evidence to recommend for or against neurofeedback. And a brain map cannot diagnose addiction, PTSD or depression. Diagnosis comes from an evaluation by a licensed clinician.

An EEG (electroencephalogram) is a test that measures the brain's electrical activity through small metal disks, called electrodes, placed on the scalp. It is a recording. It does not send electricity into your brain.

A qEEG, or quantitative EEG, adds a computer analysis. The software measures how much activity occurs at different frequencies, often called brain waves, and can show the results as charts or color maps. That picture is where the name brain mapping comes from.

The FDA regulates the devices that do this analysis. The federal rule describes them as devices that display the frequency content of the EEG signal. It does not describe them as tools for diagnosing addiction or PTSD.

Neurofeedback is a type of biofeedback. Federal rules describe biofeedback devices as giving you a visual or sound signal tied to something your body is doing, such as brain wave activity, so you can learn to control it.

In a typical session, sensors on your scalp read your brain activity while you watch a screen or listen to tones. The image or sound changes when your brain activity moves in the direction the session is aiming for. Over a series of sessions, the goal is for you to learn to shift that activity yourself.

There are different kinds. In one recent review of addiction studies, just over half used EEG neurofeedback, and those studies most often used a method called alpha-theta training. The rest used other ways to measure brain activity, such as fMRI brain scans.

Two recent reviews show where the research stands. A 2025 systematic review in the journal Psychiatry Research looked at 32 studies of neurofeedback for addiction. The main outcome the studies measured was drug craving. The authors concluded that neurofeedback shows promise as an add-on to treatment. They also noted that methods varied from study to study.

A second review, published online in 2025 in the journal Addiction, combined the results of 17 randomized controlled trials. In these trials, people are assigned to groups by chance. The trials included 662 people in total, fewer than 40 per trial on average. On average, EEG neurofeedback reduced addiction symptoms, with stronger results for substance use than for behavioral addictions. The authors also said the people studied and the methods used differed widely, and that treatment methods still need to be refined.

Taken together, the research describes neurofeedback as a possible add-on that is still being studied. It is not a proven stand-alone treatment for addiction. It belongs alongside the core parts of care, such as therapy and medical treatment, not in place of them.

For PTSD, the clearest guidance comes from the 2023 clinical practice guideline written by the Department of Veterans Affairs and the Department of Defense. It found there is not enough evidence to recommend for or against neurofeedback for PTSD. It reached the same finding for repetitive transcranial magnetic stimulation and transcranial direct current stimulation.

The same guideline strongly recommends three trauma-focused therapies: cognitive processing therapy (CPT), eye movement desensitization and reprocessing (EMDR), and prolonged exposure (PE). If neurofeedback is suggested for PTSD, it makes sense to ask how it fits with one of those therapies. Learn more about trauma and PTSD treatment.

A qEEG can show how your brain's electrical activity is spread across frequencies and across areas of the scalp. Clinicians may use that information to plan neurofeedback sessions.

It cannot diagnose a mental health or substance use condition on its own. A diagnosis comes from a licensed clinician's evaluation of your history and symptoms. For PTSD, the VA notes that only a mental health provider can make the diagnosis.

Researchers have also tested whether qEEG can predict which treatment will work. A 2019 review in the American Journal of Psychiatry combined 76 studies of qEEG in depression. It found qEEG was not clinically reliable for predicting whether depression treatment would work. It also found signs that studies with negative results often went unpublished. The authors concluded that qEEG should not be used to guide the choice of psychiatric treatment until those problems are fixed.

True Again Care is a program of FHE Health, and FHE Health offers the services this article describes. Its NeuroRehab services include qEEG brain mapping, neurofeedback and neurostimulation. NeuroRehab care starts with a qEEG, which the team uses to plan neurofeedback and neurostimulation.

These services are added to a treatment plan when clinically appropriate. They do not replace psychiatric care or therapy. FHE Health's care teams include neuro-rehabilitation specialists, psychiatrists and licensed therapists.

No one can promise how you will respond. See brain-based care for how each service is used and what the evidence shows.

Coverage for brain-based services varies. At FHE Health, some services may be covered by insurance and others are self-pay, and admissions reviews this based on your coverage and clinical need.

TRICARE covers services that are medically necessary and proven, and it does not cover unproven treatments. See insurance and TRICARE.

FHE Health does not accept Medicaid or Medicare. If you have Medicaid, Medicare or no insurance, SAMHSA's National Helpline at 1-800-662-4357 is confidential and open 24/7, or you can search FindTreatment.gov.